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Genomic studies of mood disorders - the brain as a muscle?
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Abstract
Recent genomic studies showing abnormalities in the fibroblast growth factor system in the
postmortem brains of people with major depressive disorder support previous indications of a
role for growth factors in mood disorders. Similar molecular pathways, volumetric changes, and
the effects of exercise on mood suggest a superficial analogy, and perhaps a deeper relationship,
between muscle and brain functioning.
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An evolutionary perspective on mood disorders
Mood - the way one feels inside emotionally - is likely to have
evolved, broadly speaking, as a sensor and integrator of the
environmental availability, or lack of availability, of resources
that an organism needs to live, to develop and to propagate
its genes. A non-nurturing, hostile environment engenders
low mood and depression. This is useful in making the organ-
ism conserve existing resources, keep still and stay out of
harm’s way [1,2]. Conversely, a nurturing, favorable environ-
ment engenders high mood and euphoria, making the organ-
ism more likely to take advantage of opportunities, to expand
and to propagate its genes. The switch from low to high mood
becomes loose in bipolar (manic-depressive) illness, and
overreacts to minor stimuli in an excessive and persistent
fashion that often obscures any correlation with external events
that trigger the switch. The incongruence between mood and
environment is a hallmark of severe clinical depression or
mania. In severe clinical depression (also called major depres-
sive disorder), mood is low even in favorable conditions,
whereas in mania, mood is high even in unfavorable condi-
tions. Extremes of mood are often associated with cognitive
distortions (psychotic symptoms).
Mood disorders have been studied primarily in humans,
although aspects of them can be found in other animals and
can be studied in rodent models, for example [3]. They are
the result of a complex interaction between genes and the
environment, and some people are more susceptible than
others, whether for genetic or other reasons (such as devel-
opmental insults or stressors). Little is currently known
about the genes involved in susceptibility to mood disorders
[4]. Brain-imaging studies have shown that the regions of
the brain that are important in mood regulation include the
prefrontal cortex and the hippocampus, and depression has
been linked with a decrease in volume of these parts of the
brain. Depression can be treated with a range of antidepres-
sant drugs, including specific serotonin re-uptake inhibitors
(SSRIs such as fluoxetine, one brand name for which is
Prozac, sertraline (Zoloft), or paroxetine (Paxil)). A recent
study [5] of gene expression in the brains of people with
major depression gives some insights into the genes involved
in this disorder. 
Depression and decreased growth factors
Evans et al. [5] used Affymetrix microarrays to study gene-
expression patterns in the prefrontal cortex of postmortem
human brains, focusing on subjects with depression, bipolar
disorder or no psychiatric disorder. They uncovered a down-
regulation of members of the fibroblast growth factor (FGF)
family and their receptors - with the major factors being
FGF1 and FGF2 and the receptors FGFR2 and FGFR3 - in
subjects with depression but not in the other brains. A
history of antidepressant treatment with SSRIs in the
depressed subjects seemed to mitigate this decrease in FGFs
and FGF receptors, especially for FGF2, FGFR2 and FGFR3.The connection between FGFs and depression is particularly
interesting in light of the postulated involvement of FGF2 in
the cognitive and neurotrophic effects of nicotine [6] and the
increased use of cigarettes, possibly as a means of self-
medication, in people with depression and schizophrenia
[7]. Moreover, recent work in rats has shown that a combi-
nation of the SSRI antidepressant fluoxetine and the atypical
antipsychotic drug olanzapine, which appear in human
studies to be more effective for the treatment of resistant
depression in combination than individually, led to
increased levels of FGF2 mRNA in prefrontal cortex, as well
as in hippocampus and striatum [8]. Overall, the results of
Evans et al. [5] are consistent with a body of work in vitro
and in animal models showing that antidepressant and
mood-stabilizer treatments increase the levels of neurotrophic
and cell-survival factors in the brain [9-12]. It is of interest
that the subjects with bipolar disorder in the study [5] did
not show a similar decrease in components of the FGF
system to that seen in depressive subjects; this suggests that
the decrease might be specific to the depressive state and
leaves open the possibility that the opposite may be true -
that FGFs may be increased - in more manic states, giving an
overall mixed picture in brains from bipolar patients. 
As a caveat, Evans et al. [5] present data from a relatively
small number of subjects; this is typical of the human post-
mortem work published so far and is due to the scarcity of
good-quality tissue with adequate associated phenotypic
information. The first cohort contained 9 depression,
6 bipolar and 7 control subjects; the second contained
4 depressed and 6 control subjects. Generally, given the
genetic heterogeneity of human populations and the differ-
ences in exposures to environmental factors (including
psychotropic drugs) in the lifetimes of different people, work
with postmortem human brains needs as high a number of
subjects as possible. Careful cross-validation with multiple
other independent lines of evidence is also needed, including
‘clean’ animal model gene-expression data and data on
human genetic linkage; my colleagues and I have termed this
cross-validation approach ‘expanded convergent functional
genomics’ [3].
A second caveat that should be borne in mind when looking at
the work of Evans et al. [5] is that it looks predominantly at
male postmortem brain samples; also, the samples are often
the result of violent death by suicide or accident. One question
that needs further study is whether there are differences in the
gene-expression patterns and resulting neurobiology of
depression between men and women. Clinical epidemiology
studies have consistently shown that there is a two-fold
higher incidence of depression in men than in women. The
phenomenology and environmental triggers of depression
and suicidality may be somewhat different in the two sexes -
loss of status leading to violent completed suicides in men,
and perceived abandonment leading to incomplete
attempted suicides by women [1,13,14].
Other work [12] has shown that another growth factor,
brain-derived neurotrophic factor (BDNF), is decreased in
depression, and it may also be involved in bipolar disor-
ders and schizophrenia, though this is less clear. Interest-
ingly, the work of Evans et al. [5] also found that levels of
the BDNF receptor Ntrk2 were significantly decreased in
depressed subjects. Other growth factors have been impli-
cated in psychiatric illnesses: nerve growth factor [15],
epidermal growth factor [16], and neurotrophin 3 [17].
Decreased levels of growth factors are also associated with
decreased brain volume in key areas for psychiatric illness,
such as the hippocampus [18,19].
Circumstantial evidence suggests that, conversely, an
excess of growth-factor activity might be correlated with
mania. FGFR1 and IGF1 (insulin-like growth factor 1) were
elevated in an animal model of mania [20]. Anabolic
steroids, which not only increase muscle mass but also
increase the levels of growth factors such as insulin-like
growth factor 1 in many parts of the body [21], also have
effects similar to (hypo) mania, such as elevation of mood,
hypersexuality and promotion of aggression [22,23]. Phys-
ical exercise and an enriched environment, both of which
can have mood-elevating effects, have been shown in
mouse studies to increase proliferation of hippocampal
stem cells [24-26], presumably through increased levels
and activity of growth factors [27]. 
Parallels between the regulation of mood and
muscle development
FGFs are believed to be important for the differentiation
and maturation of many tissues, including muscle. The
developmentally regulated expression and distribution of
FGFRs, especially FGFR3, play a role in muscle maturation
[28]. The fact that a molecular signaling system used for
muscle and connective-tissue development has been shown
to be downregulated in depression raises the intriguing
possibility that brain regions involved in mood are regu-
lated in an analogous way to muscle; for instance, that
these regions are atrophied in depressed people in the
same way that muscle atrophies when it is inactive for long
periods. In both brain and muscle, tissue volume and levels
of activity seem to correlate with levels of growth factors,
and sometimes the same growth factors are involved in
both tissues. It is unclear whether depression occurs
because of low growth-factor levels in key brain areas or
whether the growth-factor levels are low because those
brain areas are less active. Both may be true in varying
degrees, and the role of environmental stress as a precipi-
tant cannot be overemphasized [29]. Identifying functional
polymorphisms in  genes of the FGF system in subjects
with depression may point to a genetic component,
whether inherited or acquired. Regardless of which phe-
nomenon is the cause and which the result, the mood-regu-
lating brain regions appear to shrink the longer the person
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when they are unused. Following from the evolutionary per-
spective outlined above, we can speculate that atrophy of
brain regions in depression may be adaptive mechanisms to
a chronically deprived and limiting environment, whereas
conversely hypertrophy of brain and elevated mood would
be adaptive reactions to a supportive and resource-rich envi-
ronment (Figure 1). The same growth factors may be used in
both brain and muscle because evolution is a tinkerer and
uses the building blocks that are available.
This analogy has practical implications. The selective short-
term use of steroids with anabolic properties might be useful
for treating severe depression, albeit as a heroic measure of
last resort to jump-start recovery, on a par with electrocon-
vulsive therapy. Moreover, from a more practical standpoint,
the analogy suggests that imaging studies that measure the
volume of different brain regions [31] could be used for
assessing the severity of mood disorders and the response to
treatment. Last but not least, what is good for muscle - physical
exercise - seems to be good for the brain too [32]. Physical
therapy may become a useful supplement to pharmacotherapy
and psychotherapy, with a treadmill supplanting the
proverbial Freudian couch. The Romans may have had it
right with their ideal of mens sana in corpore sano (a
healthy mind in a healthy body).
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Figure 1
A putative model of the relationship between environmental stimulation,
growth factors, and the function of the brain regions involved in mood
regulation. The degree of environmental stimulation influences growth-
factor levels and brain volume in the brain regions that are involved in mood
regulation. In clinical mood disorders, such as bipolar (manic-depressive)
illness, there is a loosened connection between environmental reality and
internal brain functions underlying mood. 
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